Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors

Atherosclerosis

Volumn 163, Issue 2, 2002, Pages 213-222

  Maitland van der Zee, Anke Hilse ^a,b   Klungel, Olaf H ^a   Stricker, Bruno H C ^b   Verschuren, W M Monique ^c   Kastelein, John J P ^d   Leufkens, Hubertus G M ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HMG CoA reductase inhibitors; Pharmacogenetics; Polymorphisms

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; STROMELYSIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFECT; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MUTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; COST-BENEFIT ANALYSIS; FIBRINOGEN; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPASE; LIPOPROTEIN LIPASE; MATRIX METALLOPROTEINASE 3; MUTATION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0036277206     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00725-0     Document Type: Review

References (76)

1. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators
2. Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatine Survival Study
4. For the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatine in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia
7. Primary prevention of acute coronary events with lovastatine in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
8. Genomic medicine and the future of health care
9. Therapeutic lessons from pharmacogenetics
10. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators [see comments]
11. Compliance and adverse event withdrawal: Their impact on the West of Scotland Coronary Prevention Study
12. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
13. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy
14. Pharmacogenomics [interview by Clare Thompson]
15. The interface between pharmacoepidemiology and pharmacogenetics
16. Reverse cholesterol transport - A review of the process and its clinical implications
17. Role of ABC1 gene in cholesterol efflux and atheroprotection [comment]
18. Tangier disease as a test of the reverse cholesterol transport hypothesis
19. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: Role of Sp1/Sp3 in transcriptional regulation
20. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study
21. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
22. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol
23. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels
24. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia
25. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
26. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene [In Process Citation]
27. Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease
28. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction
29. Polymorphism of the cholesteryl ester transfer protein gene [letter]
30. Polymorphism of the cholesteryl ester transfer protein (CETP) gene predicts cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS) (Abstract)
31. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promotor which results in reduced gene expression
32. Interstital collagenase (MMP-1) expression in human carotid atherosclerosis
33. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
34. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina
35. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial
36. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
37. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study [see comments]
38. Fibrinogen and risk of cardiovascular disease. The Framingham study
39. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies [see comments]
40. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
41. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men [published erratum appears in Arterioscler Thromb 1994;14:1392]
42. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
43. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors
44. 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: Proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group
45. The genes coding for A alpha-, B beta-, and gamma-chains of fibrinogen map to 4q2
46. Human apolipoprotein E isoprotein subclasses are genetically determined
47. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study
48. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?
49. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia
50. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy [In Process Citation]
51. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin
52. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
53. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia
54. Apolipoprotein E phenotypes in familial hypercholesterolaemia: Importance for expression of disease and response to therapy
55. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
56. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the scandinavian simvastatin survival study [In Process Citation]
57. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
58. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner
59. Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro
60. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase
61. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis
62. A common variant in the gene for lipoprotein lipase (Asp9→Asn). Functional implications and prevalence in normal and hyperlipidemic subjects
63. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis
64. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: The Framingham Offspring Study
65. Common variation in the lipoprotein lipase gene: Effects on plasma lipids and risk of atherosclerosis
66. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis
67. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
68. ACE I/D gene polymorphism: Presence of the ACE D allele increases the risk of coronary artery disease in younger individuals
69. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease
70. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction [see comments]
71. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk
72. The angiotensin-converting enzyme deletion-type gene is associated with ischemic events and a blunted effect of lipid-lowering treatment on angiographically defined coronary atherosclerosis (Abstract)
73. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity
74. Low-density lipoprotein subclass patterns and risk of myocardial infarction
75. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
76. Assessing the cost-effectiveness of pharmacogenomics